AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be removed by surgery (borderline resectable), that has spread to nearby tissue or lymph nodes (locally advanced), or that has spread from where it first started (primary site) to other places in the body (metastatic). AB801 is a drug designed to block a protein called AXL. AXL is found on the surface of certain cancer cells and plays an important role in helping tumors grow,

Trial Details

NCT ID

NCT07619313

Phase

PHASE1

Sponsor

Jonsson Comprehensive Cancer Center

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Biopsy Procedure
Cisplatin
Computed Tomography
Durvalumab
Fluorouracil
Gemcitabine

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

Male or female ≥ 18 years of age and willing and able to provide informed consent
Previously untreated cytologically or histologically confirmed, at least one measurable lesion via Response Evaluation Criteria in Solid Tumors (RE…
Cholangiocarcinoma
Borderline resectable/locally advanced cholangiocarcinoma: to be defined as unresectable disease on evaluation by a hepatobiliary multi-disciplinar…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →